The Arachidonate 15 Lipoxygenase pipeline drugs market research report outlays comprehensive information on the Arachidonate 15 Lipoxygenase targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Arachidonate 15 Lipoxygenase pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Central Nervous System, Metabolic Disorders, Cardiovascular, and Undisclosed which include the indications Parkinson’s Disease, Pain, Type 1 Diabetes (Juvenile Diabetes), Inherited Mitochondrial Disorders, Subarachnoid Hemorrhage, Ischemic Stroke, and Unspecified. It also reviews key players involved in Arachidonate 15 Lipoxygenase targeted therapeutics development with respective active and dormant or discontinued products.
The Arachidonate 15 Lipoxygenase pipeline targets constitutes close to seven molecules. Out of which, approximately five molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Preclinical, and Discovery stages are 1, 1, 2, and 1 respectively. Similarly, the universities portfolio in Preclinical comprises 2 molecule.
Arachidonate 15 Lipoxygenase overview
Arachidonate 15-lipoxygenase (ALOX15) is an enzyme that plays a key role in the metabolism of arachidonic acid, a polyunsaturated fatty acid. ALOX15 catalyses the oxygenation of arachidonic acid to produce 15(S)-hydroperoxyeicosatetraenoic acid (15(S)-HPETE), which serves as a precursor to produce various bioactive lipid mediators, including leukotrienes and lipoxins. ALOX15 is found in various tissues and cell types throughout the body and involved in various physiological and pathological processes, including inflammation, immune response, and the regulation of lipid signalling pathways. It is expressed in various tissues and cell types throughout the body.
For a complete picture of Arachidonate 15 Lipoxygenase’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
